[
  {
    "ts": null,
    "headline": "Regeneron Announces Investor Conference Presentations",
    "summary": "TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of",
    "url": "https://finnhub.io/api/news?id=155e73048421f22255f8ab8c20965a9b718905ba690c0b6cbd281b7f6b766b10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739307900,
      "headline": "Regeneron Announces Investor Conference Presentations",
      "id": 132819283,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of",
      "url": "https://finnhub.io/api/news?id=155e73048421f22255f8ab8c20965a9b718905ba690c0b6cbd281b7f6b766b10"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=81655d9d8cf31eb7e7a16affc36650f2321e562205f68c720395ec3e0c1a3a57",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739291400,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 132686307,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=81655d9d8cf31eb7e7a16affc36650f2321e562205f68c720395ec3e0c1a3a57"
    }
  },
  {
    "ts": null,
    "headline": "Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma",
    "summary": "Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least fo",
    "url": "https://finnhub.io/api/news?id=acebe50614400c05ab8403446aca53640f880d23cc18d17999618e83f1cecc32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739275200,
      "headline": "Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma",
      "id": 132819285,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least fo",
      "url": "https://finnhub.io/api/news?id=acebe50614400c05ab8403446aca53640f880d23cc18d17999618e83f1cecc32"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
    "summary": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
    "url": "https://finnhub.io/api/news?id=e8e5dd3aa4d4ac9d9f4bf3966d15856b777bfb9bf529df9706bf0f7e0c47b83c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739259360,
      "headline": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
      "id": 132664048,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
      "url": "https://finnhub.io/api/news?id=e8e5dd3aa4d4ac9d9f4bf3966d15856b777bfb9bf529df9706bf0f7e0c47b83c"
    }
  }
]